AI Steps Into RNA Drug Discovery, From Small Molecules to Oligonucleotide Therapeutics

AI is transforming RNA drug discovery by improving RNA structure prediction and enabling the design of both small molecule and oligonucleotide therapeutics, overcoming traditional challenges in targeting dynamic and complex RNA structures. Recent FDA approvals of RNA-targeted therapeutics and advances in AI models highlight growing clinical success and expanding applications across diverse diseases.

This Wire brief sits within Fusion42's coverage of AI Frontier Models, Biotech and Drug Discovery.